|
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lymphoma viability remained unaffected by the genetic deletion or pharmacological inhibition of all alternative BCL-2 family members.
|
27055871 |
2016 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have reported micro-SPECT/CT imaging of Mec-1 human lymphoma xenografts in SCID mice, using [(111)In]DOTA-anti-bcl-2-PNA-Tyr(3)-octreotate.
|
26239085 |
2015 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, DHL and DPL are not concordant, and it is unclear whether MYC and BCL2 aberrations have prognostic impact in DPL patients.
|
25828389 |
2015 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The target genes of miRNA-342 such as B-cell CLL/lymphoma 2 (BCL2) were mainly enriched in the biological process related to cellular metabolic process and Disease Ontology terms of lymphoma.
|
25908172 |
2015 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Upregulation of hClock enhanced the activity of the anti‑apoptotic gene phosphorpylated (p‑)AKT and inhibited the expression of the pro‑apoptotic gene B cell lymphoma‑2 (Bcl‑2)‑associated X protein and Bcl‑2 homology 3 interacting domain death agonist.
|
25625359 |
2015 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicate that blood BCL2-MBR translocations represent lymphoma precursor clones with malignant potential.
|
25549806 |
2015 |
|
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with both MYC and BCL2 CNA had similar outcomes to those with classic double hit lymphoma or protein double expression lymphoma (MYC and BCL2/BCL6 coexpression).
|
26158410 |
2015 |
|
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, BCL2 mutations can affect antiapoptotic Bcl-2 function, are associated with increased activation-induced cytidine deaminase expression, and correlate with increased risk of transformation and death due to lymphoma.
|
25452615 |
2015 |
|
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.
|
24786774 |
2014 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FOXP1, p53, and BCL2 positivity was associated with poor OS with both lymphoma types but OS with DLBCL was significantly lower than with MALT lymphoma.
|
24232982 |
2014 |
|
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, BCL2 mRNA molecules correlated with IgH mRNA molecules in individual cells both in t(14;18) lymphoma cell lines and in patient samples.
|
25303368 |
2014 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphoid follicle colonization by Bcl-2(bright+)CD10(+) B-cells ("follicular lymphoma in situ") at nodal and extranodal sites can be a manifestation of follicular homing of lymphoma.
|
23363648 |
2013 |
|
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Bcl-2 protein overexpression was associated with inferior outcome in patients with germinal center subtype lymphoma, but multivariate analysis showed that this was dependent on BCL2 translocations.
|
22929980 |
2013 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, ectopic expression of Bcl-X(L) (but not Bcl-2) in two B-lymphoma cell lines decreased their sensitivity to parthenolide-induced apoptosis.
|
22155272 |
2012 |
|
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Both primary breast lymphoma and lymphoma with concurrent BCL2-IGH and MYC translocations are rare and are primarily seen in adult patients.
|
21491965 |
2012 |
|
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Among many factors that contribute to TRAIL resistance, overexpression of Bcl-2 is commonly seen in many kinds of tumors, particularly in lymphoma.
|
21988644 |
2012 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
4E-BP1 expression was also demonstrable in all 4 lymph nodes with in situ or partial involvement by follicular lymphoma and in all 12 cases of BCL2-negative lymphoma.
|
21366462 |
2011 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EZH2 mutations were frequently associated with the presence of BCL2 rearrangement (BCL2-R) in both the FL (28% of BCL-R cases versus 0% of BCL2-WT cases, p<0.05) and GCB-DLBCL groups (33% of BCL2-R cases versus 4% of BCL2-WT cases, p<0.04), and across all lymphoma types excluding BL (27% of BCL2-R cases versus 3% of BCL2-WT cases, p<0.003).
|
22194861 |
2011 |
|
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A case-control study of tobacco use and other non-occupational risk factors for lymphoma subtypes defined by t(14; 18) translocations and bcl-2 expression.
|
20232134 |
2010 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BI79D10 also effectively induces apoptosis of the RS11846 human lymphoma cell line in a dose-dependent manner and shows little cytotoxicity against bax-/-bak-/- mouse embryonic fibroblast cells, in which antiapoptotic Bcl-2 family proteins lack a cytoprotective phenotype, implying that BI79D10 has little off-target effects.
|
19372563 |
2009 |
|
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our method can quantify amounts of MYC oncoprotein and B cell lymphoma protein-2 (BCL2) in Burkitt's and follicular lymphoma; identify changes in activation of extracellular signal-related kinases-1 (ERK1) and ERK2, mitogen-activated kinase-1 (MEK), signal transducer and activator of transcription protein-3 (STAT3) and STAT5, c-Jun N-terminal kinase (JNK) and caspase-3 in imatinib-treated chronic myelogeneous leukemia (CML) cells; measure an unanticipated change in the phosphorylation of an ERK2 isomer in individuals with CML who responded to imatinib; and detect a decrease in STAT3 and STAT5 phosphorylation in individuals with lymphoma who were treated with atorvastatin.
|
19363496 |
2009 |
|
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To examine a IgH/bcl-2 hybrid gene and VH gene to investigate the nature of the lymphoma cells and how they differ from nodal follicular lymphomas and MALT lymphomas.
|
17601964 |
2008 |
|
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To better understand the mechanisms underlying the role of the immunoglobulin heavy-chain gene (IgH) 3' enhancers on bcl-2 transcriptional deregulation in t(14;18) lymphoma, we characterized the physical interactions of the IgH 3' enhancer region with the bcl-2 promoters.
|
18695675 |
2008 |
|
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data support the notion that among gastrointestinal MALT lymphomas, t(14;18)-(IgH;Bcl-2) translocation clusters in HCV-positive patients sustaining the role of HCV infection in the lymphoma development.
|
18538438 |
2008 |
|
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It is highly debated whether cases of follicular lymphoma without BCL-2 gene rearrangement and expression represent a separate lymphoma entity with distinct biological characteristics, different from the BCL-2-positive cases.
|
18945749 |
2008 |